A Serene Shore Resort, Except for the SpaceX Ball of Fire – The New York Times

BOCA CHICA, Texas The text arrived late at night: For your own safety, leave home by morning, it read. Nancy and James Crawford, no longer surprised but still unsettled, raced away in their S.U.V. after sunrise, occasionally twisting their necks to catch a glimpse of the space rocket towering behind them.

Moments later, the Crawfords, who are in their 70s, watched from a 12th-floor balcony on South Padre Island, a few miles up the coast, as the rocket shattered on impact during an attempted landing, spreading fiery debris along the sand dunes and tidal flats. The building shook, Mr. Crawford recalled, and in the distance, there was a ball of fire.

It was exciting, echoed his wife, but too dangerous if we had stayed home.

Home for the Crawfords is a remote coastal community a stones throw from Mexico, a village so small that water has to be trucked in. With a single road in that ends at the shoreline, it has long attracted people eager to escape congested cities, and retirees eager to escape the harsh winters of the North and Midwest.

From the community tucked among lush wetlands, wildlife refuges and sandy beaches, the nearest supermarket is about 20 miles away, past long stretches of gravel roads and a Border Patrol checkpoint. Until a few years ago, the handful of residents could not have imagined that rockets designed for interplanetary travel would be as much a part of their view as the Rio Grande.

But ever since the billionaire Elon Musk brought his private space company, SpaceX, to the area, life has not been the same. A gargantuan gray rocket, surrounded by chain-link fencing less than a mile from the ranch-style brick homes, is a constant reminder that the Crawfords and their remaining neighbors live near a space launching pad.

SpaceX representatives usually give the 10 or so residents plenty of warning that a rocket is scheduled for launching. Other times, loud sirens warn them, and some, like the Crawfords, choose to put on heavy-duty headphones to block some of the noise. When a rocket engine is tested, the roar and trembling are so powerful that they can blow windows inward.

Humans are not the only species who cower. The earsplitting sound of rockets shrieking above the tidal flats has caused some, such as shorebirds, to flee in terror or to stop nesting in the area altogether. And heavy machinery brought in to retrieve whatever debris has scattered often damages the road and scares away other wildlife, environmentalists said.

While the Federal Aviation Administration has given SpaceX environmental clearance for the tests, environmentalists worry that recent explosions could have a lasting effect on the ecologically rich area, home to a number of endangered species, like ocelots and Kemps ridley sea turtles.

When youre testing brand-new technology and brand-new rockets, brand-new engines, stuff like that happens, said Jim Chapman, president of Friends of the Wildlife Corridor, a nonprofit group with a mission to protect the native habitats of the Rio Grande Valley. Well, our feeling is, that shouldnt be happening here.

But the story of how SpaceX came to Boca Chica, about 22 miles from Brownsville, Texas, begins with a promise of a much-needed economic boost to one of the poorest regions in the country.

For decades, Brownsville and the broader Rio Grande Valley have struggled with a lack of opportunities and a brain drain, with many college graduates opting to leave for careers elsewhere.

Before SpaceX became entrenched in Brownsvilles consciousness, the economy had relied heavily on jobs with the government, schools, health care and some low-paying retail stores, officials said.

Representatives for SpaceX, which is investing a fortune in its quest to send people to Mars, did not respond to a request for comment. But officials of Cameron County, which includes Boca Chica, said the company had infused hope and optimism into the region.

When the company announced plans to move to the area in 2014, it promised to create about 500 jobs, said Eddie Trevio Jr., the Cameron County judge, the countys top elected official. But as of late last year, he said, the actual figure was more than triple that, with more than 1,600 jobs in construction, clerical and other fields, most of them given to local residents, he said.

The benefits to the Brownsville area, where according to the U.S. Census Bureau at least 30 percent of the population lives in poverty, will eventually outweigh whatever tension and disruptions the company has brought, Mr. Trevio said.

We have to balance the good with the bad, he said.

The search for the ideal SpaceX launching pad began more than 10 years ago. Sites were considered in other states, including Georgia, California and Alaska, with engineers needing a mostly desolate area close to the ocean. Boca Chica, a retirement community with only a few year-round residents, fit the bill.

After SpaceX signed a deal to set up operations near the village, the testing of rockets that would one day reach outer space began a few years later in earnest, Mr. Trevio said. The company has taken a fail-fast, fix-fast approach, which essentially means that engineers use the tests to identify shortcomings in the design and then make adjustments before the next test.

Over the past year, those who still live in the community have had to flee before every launch. Four rockets have exploded, spreading debris across the area. (The most recent test, this month, did not result in an explosion, and an elated Mr. Musk took to Twitter to celebrate the milestone: Starship landing nominal!)

This was not the Crawfords idea of a peaceful retirement. Both worked in government jobs in Michigan, he in law enforcement and she with a deeds department. And though they still spend their summers in Michigan, they bought their home in Boca Chica 10 years ago in search of nature and some quiet.

Then came the knocks on their door, and on the doors of their neighbors. SpaceX wanted their homes. Representatives with the space giant had appraised the Crawfords single-story, three-bedroom brick house at $50,000 and was willing to pay three times that, they were told. The Crawfords dismissed what they considered to be a paltry offer from one of the richest men in the world.

We cant buy a new house with that money, Mr. Crawford said with a chuckle.

Last October, the offers finally stopped.

We are pretty certain that we will be able to remain in our home, Ms. Crawford said with a sigh of relief.

But many of their neighbors, who like them once found Boca Chica the perfect winter oasis, took the checks and left.

And one by one, the ranch homes have been replaced by modern white houses with solar-powered rooftops, the occupants younger space professionals who work for SpaceX, residents said.

You can tell which homes are SpaceX because they are the ones that look the same, a stale white and black, said Rosemarie Workman, 72, who spends most of the year in Boca Chica and has turned down offers to sell her home.

One of her new neighbors has stood out. Mr. Musk has been spotted staying in an unassuming ranch-style house. Ms. Workman and her neighbors sometimes see him taking a stroll with two men they assume are part of his security detail.

He doesnt really make an effort to say hi or get to know us, said Jim Workman, 75, who lives across the street from the billionaire.

The feeling, he admitted, is mutual. He pointed to a flag on his front porch that reads Come and Take It below the image of a cannon, the flag fashioned for the Texas Revolution and long a symbol of defiance in the state.

I think he gets the message, Mr. Workman said.

Concerns over SpaceX extend beyond Boca Chica.

In downtown Brownsville, Elias Cantu, an activist with the League of United Latin American Citizens, the oldest Mexican-American civil rights organization in the country, stood beside a mural of Mr. Musk that read Boca Chica to Mars and shrugged. He said he feared it would be only a matter of time before Boca Chicas extreme redevelopment found itself encroaching into Brownsvilles poorest neighborhoods.

Its inevitable, Mr. Cantu said. Hell need homes to house all the people he wants to bring down here. Im afraid hes going to push out a lot of low-income families who have lived here for generations.

Xandra Trevio, a member of Fuera SpaceX, an organization pushing back on SpaceXs rapid expansion (its name translates as Leave SpaceX), said she and many other activists felt ignored by area policymakers.

I feel like people believe that SpaceX is going to be good for the community, when in fact, they are too large to control, too large to hold accountable, Ms. Trevio said. Local officials are only seeing money signs. Local officials are star-struck.

But area officials said they could not turn away millions of dollars and the promise of high-paying jobs in a region that for decades has been starved for investment.

In the build it and they will come philosophy, the space giant has already attracted other employers to the region. Space Channel, an entertainment network devoted to covering space, recently announced that it would move part of its operations from Los Angeles to Brownsville, including six executives, with local positions to follow. Other companies are likely to do the same, said Rose Gowen, who sits on the city commission.

One of the very important things for me to support, and us to support, is growing the wealth, Ms. Gowen said.

Mr. Musk seems to agree. He recently announced on Twitter that he planned to donate $30 million for city revitalization projects and schools. The mayor of Brownsville, Trey Mendez, did not respond to a request for an interview. But in a statement, he said he supported money coming in. We look forward to a discussion about how this could help our community prosper as we take a front seat to the next chapter of space exploration and innovation, he said.

But that growth is no consolation for the holdout residents of Boca Chica. The Crawfords like to sit in their backyard and admire the several species of birds looking for respite, or the delightful sightings of those migrating.

But reminders that they live near a launchpad are never far away. Every now and then, loud sirens startle them, signaling that the testing of rocket engines is about to begin. Or they receive a text asking them to leave their home, a cue that a launch is imminent.

When a sheriffs vehicle drives by with its sirens on, the Crawfords know they are supposed to run to the street or at least leave their home. They know their windows could shatter. But the last time they heard the siren, on one afternoon this spring, the couple looked at each other and shrugged.

We grew tired of running out, Ms. Crawford said. This is life near SpaceX, after all.

Read the rest here:

A Serene Shore Resort, Except for the SpaceX Ball of Fire - The New York Times

Boca Chica Boulevard sees over 200 accidents within the last year – KGBT-TV

BROWNSVILLE, Texas (KVEO) Boca Chica Boulevard in the city of Brownsville has had more than 200 accidents every year since 2018 and it is on the top 100 roads with the most traffic incidents in Texas, according to the Texas Department of Transportation.

TxDOT paired up with the City of Brownsville to build a raised median, add sidewalks, and new drainage projects, but some residents say traffic has not gotten better.

Sometimes they dont even pay attention to what theyre doing, said Mariano Abalos, an employee at a gas station on Boca Chica Boulevard. In order to get to one point they cross through [the gas station] so sometimes you see accidents.

The manager at Angelitas Casa de Cafe on Boca Chica said that he has probably seen more accidents because of the construction.

As far as accidents I believe that theyre even going further up because people not knowing which way to go, said Leal.

Leal sent us this video from the incident that took place Sunday.

Octavio Saenz, the spokesperson for the regional TxDOT, said that this part of Boca Chica has always been busy.

For us, the most important part of this road is that its one of the top 100 roads with the most incidents in the state of Texas, said Saenz.

Saenz said that the $4.7 million project started in October of 2019 with the goal to improve the flow of traffic in the city.

People coming from the south part of the road can just cut across lanes to go to the opposite side, said Saenz. That caused continuous conflict points or areas where theres a probability that people can crash.

Though construction is supposed to fix traffic, Leal said in the short term it has posed new challenges for business.

From our customers having issues being able to come into our plaza, to having issues with our plumbing when they reconstructed the sidewalk, said Leal.

Saenz said TxDOT is doing what they can and it is up to drivers to drive safe.

2020 when the number of drivers went down because of COVID-19, we expected the number of accidents to as well but no the percentage still remained the same, said Saenz. What does that tell us? That those habits are engrained and those habits need to change.

The city of Brownsville said they have asked the state to look for more modifications to improve the current traffic plan.

Saenz said that TxDOTs construction in the area is scheduled to be complete at the end of Fall 2021.

Follow this link:

Boca Chica Boulevard sees over 200 accidents within the last year - KGBT-TV

Sweden Is Building a Massive Space ComplexAnd Itll Be Europes First Orbital Launch Site for Satellites – Architectural Digest

Over the past year, SpaceX founder Elon Musk has made it known that he dreams of incorporating a new city near the companys Boca Chica, Texas, launch site into a city called Starbase. While the idea of creating a space-age haven just miles from where the Rio Grande meets the Gulf of Mexico is an as-of-yet unrealized vision, a similar spaceport halfway around the worldand in the polar opposite climatemight just serve as some inspiration as the commercial space race heats up.

Near Kiruna, Sweden, north of the Arctic Circle, Esrange Space Center is taking shape thanks to revitalization efforts overseen by the publicly owned Swedish Space Corporation. With companies in the U.S. and Europe hoping to significantly increase the number of commercial satellites launched into space this decade, the Arctic space research center first handed over to Sweden by the European Space Agency in 1972 has taken on a renewed sense of purpose.

Taking off from above the Arctic Circle has its advantages, as launching into polar orbit over the North and South poles gives satellites a more comprehensive view of Earth, while requiring less energy for a satellite to actually get into space.

Although Americans likely picture Florida or Texas as the place to launch rockets, taking off from above the Arctic Circle has its advantages. Launching into polar orbit over the North and South poles gives satellites a more comprehensive view of Earth, while requiring less energy for a satellite to actually get into space. Thats not to mention the 2,000-square-mile landing zone a relatively remote location like Esrange has to offerespecially critical given the facilitys plans to test Europes first reusable rocket by the end of 2022.

Beyond its natural attributes, the area around Kiruna already has an infrastructural head start when it comes to space travel. The Swedes have used the site for a variety of space research projects over the years, and the countrys top scientific minds are already familiar with the area thanks to the Swedish Institute of Space Physics. The space engineering Ph.D. program at Lulea University of Technology and a specialized Space High School program in Kirun also attract the next generation of (literal) rocket scientists to the area. Thats on top of the hotel, church, and visitors center, all of which can expect to see more activity in the near future.

Outside the Esrange Space Center offices.

There should be no shortage of interested parties on hand as Esrange ramps up its efforts to become Europes preeminent launching pad for orbital rockets. As The New York Times reports, German rocketry startups (one of which, ISAR Aerospace Technologies, secured $100 million in funding from an ex-SpaceX VP) are already on site testing out engines, and more are sure to follow once the launchpads that will carry orbital rockets beyond Earths atmosphere are completed.

Though the effort is certainly ambitious (and has elicited occasional concerns from locals who appreciate the areas vast wilderness), the Swedish Space Corporation believes Esrange is vital not just for the Scandinavian countrys ambitions but for the continent as a whole.

Europe really needs to build infrastructure to get to space, Swedish Space Corporation senior VP Stefan Gustafsson told the Times. We can provide a proper space base. Whether or not that ends up being the case should be clearer by the end of 2022. But if Swedens plan to launch commercial satellites into orbit ends up paying dividends, dont be surprised if spaceports are the next major infrastructural frontier.

Read the original post:

Sweden Is Building a Massive Space ComplexAnd Itll Be Europes First Orbital Launch Site for Satellites - Architectural Digest

Elon Musk reveals Starship progress ahead of first orbital flight of Mars-bound craft – The Independent

SpaceX tycoon Elon Musk has shared a picture of his latest Starship prototype, the SN16, which is being readied for the projects biggest test yet: the first orbital flight of a Mars-bound ship, due for blast off in July.

The towering 50-metre-long stainless steel craft is seen in a hangar at Mr Musks Starbase facility at Boca Chica in Cameron County, Texas, its sci-fi nose cone and fins cast against the night sky.

Starships development brings the Tesla billionaire closer to realising his dream of landing an astronaut on the hostile surface of Mars this decade, with a view to ultimately colonising the Red Planet and even constructing cities among its craters by 2050, a project that has already seen him secure a multi-billion dollar contract with Nasa.

SpaceX has ambitions to launch crewed missions to Mars as early as 2024 and currently has the field to itself, with no government agency or rival private company on course to challenge it.

Such a plan would involve Mr Musks company building up to 100 Starships a year, with each one capable of housing 100 crew members and boasting private cabins, large common areas, centralised storage, solar storm shelters and a viewing gallery, according to SpaceXs user guide for the rocket.

The firm only began testing Starship prototypes in January 2020 but has so far set about its task at an astonishing rate.

After two successful 150-metre hops at its Starbase centre, SpaceX began a series of high-altitude flight tests at a frequency of nearly one a month. Although the first four of these ended in explosions, each represented a milestone in Starships progress.

Alongside Starship, the company is also building a 70-metre Super Heavy booster that will also be fully reusable and capable of supporting regular rocket launches from Earth.

When combined, this two-stage rocket will stand at 120 metres and make for the worlds most powerful launch vehicle ever developed.

The craft features six Raptor engines fed with liquid methane and liquid oxygen by propellant tanks, producing methalox in a combustion process that takes place in several stages, the engine design serving to minimise waste, according to the BBC.

Mr Musk hopes the use of methane as its fuel will mean it can be synthesised with subsurface water and atmospheric carbon dioxide should it eventually reach Mars, creating a Sabatier reaction that would enable it to power its way back to Earth self-sufficiently.

The Super Heavy rocket will meanwhile be filled with 3,400 tonnes of cryogenic methalox and be powered by a further 28 Raptor engines, providing 72 Meganewtons of maximum thrust and rendering it more powerful than the huge Saturn V launcher that was used for the Apollo Moon missions in the 1960s and 70s.

Speaking at a Nasa panel event in April, Mr Musk observed that it is now almost 50 years since man last landed on the Moon and commented: We need to have a big permanently occupied base on the Moon, and then build a city on Mars and become a spacefaring civilisation. We dont want to be one of those single planet species, we want to be a multi-planetary species.

The tech developer has previously described his motivation as lying in the prospect of existential threats to our planet, telling a conference in Mexico in 2016 that the future for the human species amounts to staying on Earth and awaiting some eventual extinction event - like the planet succumbing to the effects of the climate crisis or being struck by an asteroid - or establish new colonies elsewhere to increase humanitys chances of survival.

Mr Musk has been serious about cultivating life on Mars since at least 2001, when he attempted to buy three intercontinental ballistic missiles for $20 million in order to blast a robotic greenhouse to the planet in order to grow plants in its soil.

Continued here:

Elon Musk reveals Starship progress ahead of first orbital flight of Mars-bound craft - The Independent

Mike Tyson says psychedelics saved his life, now he hopes they can change the world – Reuters

During his reign as heavyweight champion of the world, no one was more feared than Mike Tyson, who obliterated opponents with ruthless efficiency.

But all the while, the troubled superstar was at war with himself, battling an abusive voice in his battered head that led "Iron Mike" to the brink of suicide.

He said that all changed when he began taking psilocybin mushrooms, more commonly known as "magic mushrooms," and other similar consciousness-altering substances.

Now the boxing prodigy from Brooklyn is experiencing a career renaissance that he said is the result of psilocybin-powered mental and spiritual exploration.

"Everyone thought I was crazy, I bit this guy's ear off," an upbeat Tyson told Reuters, referring to his infamous 1997 fight against Evander Holyfield.

"I did all this stuff, and once I got introduced to the shrooms ... my whole life changed."

To be sure, many people have had negative experiences with psilocybin, which can cause disturbing hallucinations, anxiety and panic. Medical professionals studying them warn against self-medicating or using them outside of an approved medical framework.

But Tyson, who turns 55 next month, and impressed in his November exhibition bout against Roy Jones Jr, said he has never felt better.

"It's scary to even say that," said Tyson, who is also a cannabis entrepreneur and podcast host.

"To think where I was - almost suicidal - to this now. Isn't life a trip, man? It's amazing medicine, and people don't look at it from that perspective."

"I AM CURED"

Humans have been ingesting psychedelics since the earliest days and as stigmas slowly dissolve, it is beginning to be taken seriously as a psychiatric medicine.

There is still much to learn.

Enter former NHL enforcer Daniel Carcillo, who was nicknamed "Car Bomb" for his violent approach to the sport.

After 164 fights, thousands of hits and at least seven concussions, the two-time Stanley Cup champion was forced to retire in 2015 due to repeated head trauma.

Like Tyson, he was at war with himself and struggling to connect with his wife and young children after his retirement at age 30.

He said psilocybin helped him bridge that gap and the experience led him to found Wesana Health, a first-of-its-kind company dedicated to studying its ability to treat traumatic brain injury (TBI) in athletes, veterans and others.

Wesana recently entered into a clinical research project with the World Boxing Council (WBC) to examine the potential of psilocybin to help boost the brain health of boxers, and Carcillo says he is proof that it works.

"I am cured, for sure, of TBI and any related symptoms. 100%," Carcillo said.

"I do not suffer from slurred speech, headaches, head pressure, insomnia, impulse control issues, anxiety, depression or suicidal ideation," he said.

"I do not suffer from any of that (anymore)."

Carcillo and his team are hopeful psilocybin will become an FDA-approved drug to treat TBI.

OPEN TO THE WORLD

Tyson said he wants to spread word of the benefits of psilocybin as widely as possible, which is why he has partnered with Wesana.

"I believe this is good for the world," said Tyson, who said he thinks its use could also help create a more empathetic and just society.

"If you put 10 people in a room that don't like each other and give them some psychedelics, they'll be taking pictures with each other," he said.

"Put 10 people in a room who don't like each other and give them some liquor, and they'll be shooting everybody. That's real talk.

"(Wesana) was on the same level of thinking that I was. They wanted to share this with the world. This is very limited, us doing this in these small ceremonies.

"It needs to be open to the world."

Our Standards: The Thomson Reuters Trust Principles.

Read more:

Mike Tyson says psychedelics saved his life, now he hopes they can change the world - Reuters

Are psychedelics the whole answer? | MHT – Mental Health Today

Psychedelic drugs such as psilocybin, used in combination with talking therapy, are opening new avenues of possibility within mental health care by offering a very different mechanism of treatment from existing psychiatric medications. By inducing a unique state of consciousness, these drugs temporarily alter peoples perception of themselves and their experiences.

This altered state of consciousness creates a window of opportunity by allowing thought processes and perceptions to occur in novel ways, which can enable people to approach their problems from a new perspective. Creating the right conditions for people to confront their distress, so they can generate new solutions for resolving their problems, is what separates psychedelic drugs from the way in which we use other medications, which may only provide short-term relief. Expecting psychedelic drugs to do all the work on their own, however, is not helpful for the advancement of mental healthcare; it is the talking therapy which targets psychological reorganisation that must be focused on.

Mental health difficulties are not caused by biochemical imbalances in the brain. Our mental health is multifaceted and influenced by numerous factors, such as chronic stress, historic trauma, levels of social support, and the meaning we make of it all. Working with mental health issues, therefore, is not just about creating changes to receptors in the brain; it is about having a multifaceted approach to dealing with the very idiosyncratic issues that lead to people becoming distressed.

A drug-centred, dose-response approach in psychedelic research may, misleadingly, communicate that mental health issues are simply the result of some deficit that needs to be rectified and the drug alone is the vehicle of change.

Losing focus on the role of therapy risks overplaying the importance of neurological mechanisms that contribute to mental health, whilst underplaying social, cognitive, emotional, and behavioural processes underlying mental distress.

It might be dangerous to regard psychedelic drugs as silver bullets that can directly solve mental health problems. This is a reductionistic understanding of the problems that affect peoples mental health and one that could give false hope to those who seek help. Early-stage clinical research indicates that psychedelics could be an important component of what must be a multifaceted approach, where emphasis on psychological processes is, at least, as important as what is happening biologically.

Psychedelic drugs may help people experience their problems in ways that they havent been able to before, leading to novel insights which potentially allows new solutions to be generated. In this respect, the drug is more of a catalyst that can enable people to develop awareness of the root causes of their difficulties. To quote the director of the Multidisciplinary Association for Psychedelic Studies (MAPS), Rick Doblin in the New York Times, Its not the drug its the therapy enhanced by the drug.

Psychological support provided during psychedelic-assisted therapies, whether it is non-specific support or shaped by a therapeutic model, is designed in three phases: preparation, dosing, and integration. In preparation, the therapist builds a therapeutic alliance with the participant and prepares them for what to expect. The drug is administered in the dosing session in which the therapist(s) supports the participant for the duration of the drugs effects. The integration phase focuses on making sense of the experiences the participant had during dosing and on helping them incorporate the insights and lessons learned into their daily lives.

It is widely posited that the integration phase plays an important part in generating insights from psychedelic experiences and facilitating the chance of meaningful long-term change. Yet, clinical research into what the specific mechanisms of change are and the most efficacious methods for facilitating such change is limited. A clear, empirically sound framework of understanding is needed, which provides a coherent understanding of individuals mental distress and informs a clear set of principles on which interventions can be based.

People who seek treatment from mental health services often experience multiple and varied issues, yet current practice usually involves providing a problem specific intervention based on a diagnosis. For example, there are hundreds of problem-specific talking therapies, which can be confusing for service users and unduly expensive when training mental health service providers in hundreds of approaches. We therefore need approaches that place the individual at the centre and can deal with the varied problems they face from their perspective.

Our upcoming trial, a collaboration between the University of Manchester and Clerkenwell Health, aims to investigate the impact of talking therapy alongside two different doses of psilocybin. The therapy is informed by Perceptual Control Theory (PCT), which understands mental health issues as the result of a person having reduced or loss of control over the things they value in life, usually because there are two or more competing goals that are mutually incompatible.

PCT provides an empirical framework of understanding that helps to integrate findings from across the mental health literature and informs clinical practice by identifying and capitalising on key principles common to many effective psychotherapeutic interventions. This framework advocates helping people develop their own solutions to problems by mobilising their attention to different aspects of their experiences in order to evaluate them from different perspectives.

There is an emphasis on helping people develop awareness of important values and goals so that they can work out new ways to balancing competing needs. In this respect, psilocybin may serve a useful role in helping an individual redirect their awareness to what is most salient for them, as opposed to other more directive therapeutic approaches.

A number of other therapeutic approaches are emerging for psychedelics, including the Psychedelic Harm Reduction and Integration framework used by MAPS, which has yielded promising results in early research trials. Research in this field is still in its infancy, yet what is becoming increasingly clear, is that service users must be at the centre of psychedelic-assisted therapy and the therapists role should be to guide rather than instruct.

In the Clerkenwell Health trial, psilocybin is understood as temporarily reducing our use of strategies to control experiences, including those that may be counterproductive like worry and rumination. This enables us to be exposed to emotions and wider experiences that we might not have been able to identify or focus on before.

In conclusion, we cannot expect the drug to do all the work on its own. We need more focus on the therapy, which creates the conditions required for people to get themselves better. If we want to improve clinical practice for those who seek help, a principles-based, theoretically driven approach, which builds on what is known to be useful across different psychotherapies is essential. This needs more clinical research. Developing best practices through clinical research, and more importantly, sharing these practices, is crucial for psychedelic-assisted therapy to be incorporated into mainstream clinical practice.

Visit link:

Are psychedelics the whole answer? | MHT - Mental Health Today

Psychedelic Therapy: Uses, How It’s Done, Risks, and More – Healthline

Psychedelic therapy (sometimes referred to as psychedelic-assisted psychotherapy, or PAP) is a type of psychiatric practice that involves ingesting a psychedelic substance as part of a psychotherapeutic process.

In psychedelic therapy, the use of psychedelics is typically combined with talk therapy.

A range of consciousness-altering psychedelic drugs are currently being used or researched for therapeutic purposes in both clinical and nonclinical settings.

Some are derived from plants, like psilocybin (magic mushrooms), DMT, peyote, ayahuasca, and ibogaine. Others including ketamine, MDMA, and LSD are chemical compounds.

While Indigenous communities have used psychedelics in therapeutic and religious settings for centuries, psychedelic therapy is relatively new in Western clinical settings.

Its becoming more popular with increased legalization of certain psychedelic substances, a rise in mental health conditions, and a lull in psychopharmacological research.

Between the 1950s and 1970s before former President Richard Nixon outlawed them with the Controlled Substances Act scientists produced a breadth of evidence both verifying and pointing toward the therapeutic potential of psychedelic therapy to treat:

In recent years, renewed interest and investment have fueled additional research, much of which is ongoing.

Heres a look at the potential uses of various psychedelics.

Ketamine is the most-studied psychedelic drug for mental health therapy.

In low doses, it has shown to be beneficial in numerous trials exploring its potential to treat depression, but its effects are short-lived.

For people with severe depression, for example, research shows significant improvement after treatment, and results last about 6 to 8 weeks, on average.

These findings have led to the development of a drug called Spravato. Its a nasal spray that delivers the active ketamine ingredient. However, intravenous ketamine administration is considered to be more effective and less expensive.

Multiple phase 2 clinical trials which are done to discern whether a treatment works suggest that MDMA can treat PTSD symptoms for up to 4 years.

Researchers have also completed a phase 3 trial, which determines whether a treatment works better than whats currently available, involving MDMA-assisted therapy for PTSD. This was the first phase 3 trial of any psychedelic-assisted therapy.

Among 90 participants with severe PTSD, 67 percent no longer qualified for a PTSD diagnosis after three treatments, and 88 percent had reduced symptoms of PTSD.

The trial sponsor, the Multidisciplinary Association for Psychedelic Studies, says the results could make way for Food and Drug Administration (FDA) approval by 2023.

Psilocybin, the main compound in magic mushrooms, has shown positive results in treating depression and anxiety in people living with terminal illnesses.

Experts believe it could also help with obsessive-compulsive disorder, addiction, and treatment-resistant depression, but more research is needed.

LSD, a long lasting, potent psychedelic thats considered to be the prototype for therapeutic psychedelics, has been shown to help with both alcohol use disorder and anxiety in people living with terminal illnesses.

At this stage, clinicians are still evaluating the effectiveness of their treatments, so exact dosing, number of treatments needed, and the approach to psychedelic therapy will vary depending on who is guiding you.

That said, most psychedelic therapy in clinical settings is conducted via three stages:

The first step is usually a preparatory consultation to ensure that you dont have any contraindications to the treatment. This is also a good opportunity to discuss your personal background and any goals or concerns you have around psychedelic therapy.

The second phase involves ingesting, either orally or via injection, the psychedelic substance under the supervision of a trained therapist.

There are usually multiple sessions, depending on the type of psychedelic and the treatment plan. For example:

The final phase is the integration process, when the therapist and client work together to integrate meaning from the psychedelic experiences.

Some experts have expressed concerns at the rise of self-medicating, particularly after the 2020 Global Drug Survey showed an increase in the number of people who say they are self-treating various mental health concerns with psychedelics.

Many of these concerns stem from the potential contamination of substances that dont come for a lab-tested source, along with the lack of medical supervision.

Otherwise, psychedelic substances are generally considered low risk, especially when used in a clinical setting.

MDMA can sometimes cause short-term high blood pressure, increased heart rate, and elevated body temperature, but these effects typically go away after use.

Psilocybin may similarly elevate blood pressure temporarily or cause light headaches.

That said, psychedelics have been linked to an increased risk of psychosis in people with psychotic disorders or a predisposition to them.

Theres also the risk, particularly with LSD use, of hallucinogen persisting perception disorder (HPPD). This is a rare condition involving intense flashbacks and hallucinations. However, experts note that this appears to be more common when using substances without medical supervision.

There are a few concerns about ibogaine, including a possible link to potentially fatal cardiac arrhythmias. As a result, its been limited to observational trials so far with a focus on treating opioid addiction.

Theres a lot of excitement around the potential of psychedelic therapies. As a result, a lot of new therapists, gurus, international retreats, and clinics are opening up.

If youre interested in participating in a psychedelic-assisted treatment in a clinical setting supported by an expert, a good place to start is the database of accredited therapists maintained by the Multidisciplinary Association for Psychedelic Studies.

The association also welcomes questions or concerns about psychedelic-assisted therapy, and can make recommendations to help guide you.

Whether its a clinical setting or a retreat, its important to understand that ingesting psychedelic substances alters consciousness and can make you vulnerable to suggestion.

As a result, some participants in studies or treatments have alleged unethical and sometimes even criminal behavior. Read reviews, evaluate accreditation, and consider how you might ensure accountability should anything go awry during or after treatment.

Theres still a lot to learn about the potential of psychedelic therapy, but the existing research is promising, particularly for those with severe PTSD.

Because of this, advocates and lobbyists are working to decriminalize some psychedelic substances to improve access and research opportunities. Stay tuned, because these treatment options are evolving each week.

Kate Robertson is a Toronto-based editor and writer who has focused on drugs, primarily cannabis, since 2017. She has been published in The Guardian, Macleans magazine, the Globe and Mail, Leafly, and more. Find her at @katierowboat.

Link:

Psychedelic Therapy: Uses, How It's Done, Risks, and More - Healthline

Interest in the medical use of psychedelics increasing – Business in Vancouver

Perry Chua, chief creative officer for NeonMind Biosciences Inc., a company pursuing research into the medical benefits of psychedelic drugs|Chung Chow

Psychedelics arent just for Woodstock anymore.

In a quest to fill a seemingly insatiable appetite for new markets and after witnessing the success of the cannabis industry, many venture capitalists are looking for investment opportunities on the frontiers of research into psychedelic drugs.

Right now there seems to be a tremendous amount of interest in getting these ideas up, running and funded, said Robert Tessarolo, president and CEO of NeonMind BioSciences Inc. (CSE:NEON). Theres a lot of wind in the sales of this industry, money flowing in, capital flowing in.

Psychedelics are being used to treat health issues ranging from post-traumatic stress disorder to obesity. Proponents claim that the way psychedelics affects users thinking can allow patients to confront deep subconscious issues and address the root of the problem.

Pharmaceutical discovery and development are global industries, so the potential business case is very attractive to junior, boutique-based pharma development companies and big pharma, too, said Calum Hughes, CEO of Kelowna-based Allied Corp.

The industry is forecast to grow to US$6.8 billion in North America by 2027 according to Data Bridge Market Research.

Tessarolo is the former CEO of Vancouver-based Mind Medicine (MindMed) Inc. (Nasdaq:MNMD). In early 2020, MindMed became the first psychedelics company to go public, and in a little over a year, more than a dozen others have followed suit. From September 2020 to January 2021, psychedelic stocks raised more than US$500 million.

Payton Nyquvest, president and CEO of Vancouver-based Numinus Wellness Inc., said the rising entrepreneurial interest stems from increasing concern over mental health paired with doubts about the effectiveness of many current medicines and treatments. At the same time, more relaxed legislation surrounding controlled substances is allowing for more research into beneficial uses of illegal drugs. The company is expanding its Nanaimo facility, which is licensed under Canadas Controlled Drug and Substances Act, to produce a variety of psychedelics, including LSD, MDMA, DMT, ketamine and psilocybin, the hallucinogenic substance found in psychedelic mushrooms. Hughes said that while cannabis legalization enabled physicians and scientists to research the benefits of cannabinoids, it also more recently allowed them to look at psilocybins medical benefits.

Tessarolo said the resurgence of research sparked entrepreneurial interest in psychedelics as a legitimate life sciences enterprise, under a more receptive regulatory regime willing to provide special status for psychedelics and, in one case, even approval for use.

While relaxed regulations for cannabis helped open the door for psychedelic testing and acceptance, Tessarolo insists this isnt Cannabis 2.0. For decades, there was a large, grassroots cultural movement around cannabis that touted the benefits of medical marijuana as well as the negative consequences of criminalization. Medical marijuana was largely seen as a step towards broader legalization. The same cant be said for psychedelics. Even though psychedelics have permeated popular culture, there arent annual demonstrations for mushroom legalization. Instead, companies are leading the decriminalization effort by seeking Health Canada and U.S. Food and Drug Administration (FDA) approval in a way more akin to the process for traditional pharmaceuticals.

Tessarolo said his company and others like the pharmaceutical paradigm, and he doesnt think broader legalization is needed.

Ultimately, we believe at NeonMind that the greatest chance that psychedelics have to affect the largest number of patients is with strict regulation through the FDA or Health Canada, said Tessarolo. We dont see this as being a legalization effort.

But not everyone agrees.

Nyquvest said that a patients access to new treatments should be prioritized. And while the pharmaceutical model may work for synthetic drugs like MDMA, Nyquvest said he is concerned that applying the model to naturally occurring substances could raise corporate intellectual property concerns above patients interests.

These are molecules that have occurred in nature for tens of thousands of years, and we need to really look at what accessibility looks like. You look at the amount of people suffering, theres no shortage of market that is desperately needing new treatment, so I think that needs to be the focus of all companies in this space.

Read more here:

Interest in the medical use of psychedelics increasing - Business in Vancouver

Shroom boom? Here’s why investors say psychedelics are the next stock to watch. – 13newsnow.com WVEC

Medical research is proving the potential psychedelic mushrooms hold when it comes to healing mental health. Now, investors are looking to cash in.

VIRGINIA BEACH, Va. Inside of an unassuming building in Virginia Beach, something is growing.

Its where Ryan Staabs fascination for shrooms blossomed.

After learning about the benefits of different mushroom varieties, he turned it into a business: Capstone Mushrooms. Its an indoor farm of sorts, where he grows and sells hard-to-find gourmet mushrooms.

There are mushrooms that can help heal your brain, help you think better, mushrooms that can inspire you, build your immune system, said Staab. When I thought about that, I thought I have to make this available to more than just myself, so I became diligent, on a mission.

Staab says theyre herbal and medicinal, and they deliver benefits without getting you intoxicated. In other words, theyre not "magic" mushrooms.

But across the world, scientists are giving magic mushrooms the serious treatment. New studies are finding magic mushrooms, also known as psychedelics, can heal us and could potentially be used as therapeutics for mental illness.

I think its gonna blow up, said Dr. Matthew Johnson, a Professor in Psychiatry and Behavioral Sciences at Johns Hopkins University.

During a recent study, his team discovered that just two doses of the psychedelic substance Psilobin sharply reduced depression and curbed smoking addiction. Already, several states have moved to decriminalize psychedelics, including Oregon and Washington D.C.

I think theres incredible potential here. I really do think it's gonna be a new paradigm within psychiatric treatment, said Johnson. Its a new treatment model, and theres a lot of opportunities. Thats gonna come with both the positive and challenges. This stuff has to be done safely.

This is just the start of an even bigger story. Experts believe the psychedelic research happening worldwide will lead to a major shroom boom when it comes to investing.

Gabe Rodriguez, the head of investor relations at psychedelics company E-Have said its just the beginning.

This is the time, said Rodriguez. If you missed the run on cannabis, youve got psychedelics.

Rodriguez added, "We think psychedelics is gonna make the cannabis sector look like childs play. If you got burned on the cannabis side, that means you came in toward the end of the sector when it was hot. So, how about you turn it around and come into the psychedelics sector when its hot instead of when its already running on top?

For now, Staab is soaking up all the benefits non-magic mushrooms have to offer. He packs them up into small boxes and sends them off to various farmers' markets and grocery stores throughout Hampton Roads.

Staab hopes to make an impact one shroom at a time.

Read more:

Shroom boom? Here's why investors say psychedelics are the next stock to watch. - 13newsnow.com WVEC

NIH Director Praises Psychedelics’ Potential As Therapeutic Treatment, Touts Progress In Access To Cannabis For Research – Benzinga

During a WednesdaySenate budget hearing,Francis Collins, director of the National Institutes of Health (NIH) expressedpositive remarks about the therapeutic potential of psychedelics such as psilocybin and MDMA.

I think as weve learned more about how the brain works we began to realize that these are potential tools for research purposes and might be clinically beneficial, Collins said.

The NIH is the countrys main health agency responsible for public health research. As its director, Collins stands as the highest ranking health officer in the federal government.

Psychedelics: Collins said there has been a resurgence of interest in psychedelic drugs, which for a while were sort of considered not an area that researchers legitimately ought to go after.

He went on to explain that psilocybin has been tested in three randomized, controlled trials for depression, showing signsof potential interest.

That could be quite exciting, because we all are looking for new approaches to that.

Collins added that MDMA and LSD are also under research and acknowledged that psilocybin is the psychedelic molecule that hasgarnered the most attention of late.

He told the committee hearingthat he hasbeen inconversations with the National Institute of Drug Abuse and the National Institute of Mental Health about whether its a good moment to consider having perhaps a workshop to say, OK, what have we learned so far and what more might we want to do as far as designing the next generation of clinical trials to see where these provide benefits going beyond depression to such things as PTSD?

These agencies, he estimates,will want to have a hard look at these treatments over the course of the next year.

Medical Cannabis: The NIH directoralso referred to progress being made in access to medical marijuana for federal research.

Were making some progress. You may know that in the past, researchers who wanted to do clinical studies on marijuana had all kinds of limitations," Collins said, adding that for the past five decades there had been onlyone source of marijuana for federal research purposes.

That of course is an issue because its a limited opportunity for access.

Collins said that the DEA hadrecently grantedpermission to expand the number of research marijuana providers.

However, Collins said,the best solution is to remove cannabis from its classification as a Schedule I drug.

What we really need is to moderate the schedule 1 limitation, Collins said, proposing the creation of a Schedule 1R category that would create a different pathway for researchers.

Read more:

NIH Director Praises Psychedelics' Potential As Therapeutic Treatment, Touts Progress In Access To Cannabis For Research - Benzinga

Ive experimented with psychedelic drugs to improve my mental health dont call me a waster – The Independent

Theres a strength and a maturity in seeing things the way they are and not how you want them to be. MDMA and psychedelic therapy have been used as tools for tackling trauma. It may not fit in with everyones narrative, but its about time we integrated psychedelics into mental health.

There has never been a better time to talk about the mental health benefits of psychedelics than in the midst of a global pandemic. In England, the Centre for Mental Health has predicted that up to 10 million people close to a fifth of the population will need mental health support as a direct consequence of Covid-19.

This week, BBC Two aired The Psychedelic Drug Trial, which follows research on the effects of psychedelic drugs on mental health, and in March the worlds first psychedelic-assisted therapy clinic of its kind opened in Bristol. Behind this revolution in mental healthcare is UK-based scientific group, Awakn Life Sciences. The biotechnology companyis pioneering psychedelics with psychotherapy as the next evolution in psychiatry. The scientific team is being led by Professor David Nutt and Dr Ben Sessa, author of The Psychedelic Renaissance.

Ive used psychedelics and anti-depressant drugs to help me with my mental health. The prescription drugs dont work. Ive been prescribed antidepressants a few times, during the darkest periods of my life. With antidepressants, my personality changed from being expressive to distant and vague.

I felt other to myself, so I self-medicated with psychedelics. I already knew about their unique properties as I had experimented with them when I was studying philosophy; they helped me grapple with concepts beyond my comprehension. Taking psychedelics allowed me to navigate my way through my emotions in a way that I had never been able to do with antidepressants. Instead of feeling detached from myself, as I had with the prescribed drugs, I felt engaged. Antidepressants take you away from yourself psychedelics introduce you to yourself.

Its important to state that drugs are not all the same. MDMA and psychedelics dont belong in the same category as drugs like heroin and crack. The former dont make you go against society they do the opposite they make you empathetic towards others. I take umbrage at being thought of as a waster because of my knowledge of MDMA and psychedelics. People shouldnt be crucified in their quest for truth.

Our preconceived notions of these drugs need to be challenged. A great many people like me, deemed normal, are curious and experimental. Were university lecturers, scientists, writers, office workers and every other profession you can think of. Its abominable that people who suffer from treatment-resistant depression have not been getting the help they need because of archaic and inaccurate views on psychedelics.

Im not naive about these drugs you need to be sensible when taking psychedelics. They are mind-altering they cut through the mesh of your existence. Some people are fearful of this because they think psychedelics offer a false reality, but all our realities are already skewed.

There are so many things that we are blind to; were unable to hear certain frequencies or see certain colours, there are whole worlds that exist outside our perceived perception. Even the language we speak affects our perception of reality, and only allows us to see a fraction of life.

In these unprecedented times, weve had to adapt to a new normal. There has never been a better time to open our minds and embrace the science of psychedelics. Its time we reconsidered our views on psychedelics, and properly appreciate the evidence-based psychedelic research. As my own experience has confirmed, they have great value when it comes to mental health.

Read the rest here:

Ive experimented with psychedelic drugs to improve my mental health dont call me a waster - The Independent

Can Psychedelics Actually Cure Depression and PTSD? – The Motley Fool

Is there about to be a psychedelic drug boom in mental health treatment? In May researchers released data from a phase 3 trial that used MDMA (street name: ecstasy) along with talk therapy to treat people who have post-traumatic stress disorder (PTSD). And COMPASS Pathways (NASDAQ:CMPS) is exploring the use of psilocybin (the active ingredient in "magic mushrooms") in combination with talk therapy, to treat people who have severe depression.

How big is this possible new market going to be? Corinne Cardina, bureau chief of healthcare and cannabis at Fool.com, and Motley Fool writer Taylor Carmichael discuss this emerging new treatment paradigm in a clip from Motley Fool Live,recorded on May 14.

Corinne Cardina: Do you want to go ahead and jump into psychedelics?

Taylor Carmichael: Sure.

Cardina: All right. Speaking of risky, and biotech, and cutting-edge technology in the healthcare space, there has been some exciting developments in psychedelic drugs. Last week results from a phase 3 trial of MDMA, which is actually combined with talk therapy in this trial, targeting post-traumatic stress disorder, really blew everybody away. The remission rates in this trial were double that of a placebo. The results are going to be published in the Nature Medicine journal and according to The New York Times, FDA approval could come by 2023. What is the potential market for PTSD that could be treated with MDMA? What do we know about this market?

Carmichael: Well, there are a lot of people that have post-traumatic stress disorder. A lot of it's soldiers, but there are also civilians, ordinary people who have traumatic events in their lives and it affects them. I think the market opportunity that I saw was anywhere up to, I want to say $80 billion. Let me check my notes real quick. $20 billion to $80 billion was the market opportunity. One, for people who don't know, MDMA is ecstasy. This is a drug that's been illegal for a long time. What they're doing, they're giving ecstasy to people with PTSD, and they're combining that with talk therapy. It's highly regulated, it's not just people going off on their own and using drugs. They take ecstasy and then the therapist talks to them through the experience and chats with them through the experience. We're going to talk about ecstasy and magic mushrooms, just to use the street terms. Those are two things, they both require talk therapy. That's an interesting aspect. I think in healthcare, what we've seen over the last several decades is talk therapy has declined, and has been replaced with people on depression using drugs. The pharmaceuticals, Prozac and Zoloft and all these drugs that are to help with depression. Talk therapy, which has always been expensive has declined and people taking drugs instead. Well, this kind of flips it on its head and we're back to the importance of talk therapy. In this trial, they gave the people ecstasy and then they had counselors talk them through it. Obviously, you know if you had ecstasy or have not had ecstasy, so I don't know how good they were at masking the (placebo) versus the real thing. But they also did talk therapy with people who do not have ecstasy. But they saw dramatic improvements in the people that had ecstasy and were able to talk to their therapist about their issues and they're not exactly sure how the science works. Part of it is, the experience decreases your fear, and it makes you feel, I guess safe, but decreases your fear. As such, you're able to talk about traumatic events without getting upset by them. Just that talking of it takes away a lot of the stress and a lot of anxiety. Apparently, it has been very successful.

Cardina: It's for severe PTSD. It's called MDMA assisted therapy. Like you said, it's not people getting street drugs and going to their house and trying to work through things, it's very controlled. But like you said, I think what's interesting about this is a double-blind study, it's already been published in Nature Medicine. It's a really interesting read if you're interested in this. But it is hard to mimic MDMA if you're in the placebo. Definitely, I'm curious about that. I haven't read through the whole thing. But it's really interesting because it's a cutting-edge field in healthcare. Harkens back to the early days of medical marijuana. There may be some parallels in terms of the market as we overcome stigmatization and try to find medical applications.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Read more here:

Can Psychedelics Actually Cure Depression and PTSD? - The Motley Fool

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week – Yahoo Finance

Welcome to the Cannabis Countdown, the Legal Marijuana Industrys Number One Curated Weekly News Recap.

In This Weeks Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of May 17th 23rd, 2021.

Without further ado, lets get started.

10. Red White & Bloom Announces Successful Launch of High Times THC Products in 23 Michigan Dispensaries

With Michigans Marijuana Market Continuing its Rapid Rise, the MRA Reported April Sales in the Great Lakes State Reached USD $154 Million, Putting the States Cannabis Market on a Current Annualized Run-Rate of USD $1.85 Billion

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) announced on Tuesday the successful launch of the companys High Times branded THC products in 23 Michigan dispensaries throughout the majority of the Great Lakes State. Within the first two weeks, RWBs initial CDN $1.25 million order was already 60% sold. As evidence of the popularity of the iconic High Times cannabis brand in Michigan, some retailers saw their High Times THC pre-orders exceed 10% of their dispensarys total inventory.

READ FULL RWB ARTICLE

9. New Field Trip Study Suggests Americans Open to the Idea of Psychedelic Treatments

Though There Have Been Positive Stories About Those Who Took Time to Reconnect With Family, Enjoy a Slower Pace of Life, and Exercise More During the Covid Crisis, Over Eight Out of Ten Americans Surveyed By Field Trip Reported at Least One Symptom of Depression

The results of Field Trip Healths (CSE: FTRP) (OTC: FTRPF) first annual State of Mind survey hold few surprises for those who have followed the news around the effects of the pandemic on mental health. Field Trip Health is the largest provider of psychedelic therapies in the world and initiated this survey to look into the state of mental and emotional health in the U.S., and to get a sense of how receptive respondents are towards incorporating psychedelics into treatment.

Story continues

READ FULL FTRP ARTICLE

8. Aurora Cannabis to Commence Trading on NASDAQ

The Move to the NASDAQ is Reportedly Part of the Firms Efforts to Reduce Costs

Aurora Cannabis (TSX: ACB) (NYSE: ACB) (FRA: 21P) reported that the company has completed the transfer of its stateside listing to the NASDAQ Global Select Market, from that of the New York Stock Exchange after yesterdays closing bell. The planned transfer was originally reported on May 13. The company this morning is set to commence trading on the Nasdaq following the transfer while maintaining the symbol ACB.

READ FULL ACB ARTICLE

7. MindMed Announces the Approval of Mescaline Study

Mescaline is a Classic Serotonergic Hallucinogen, Similar to LSD and Psilocybin, With a Long, Non-Regulated History of Spiritual Use

MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ) announced the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study). The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland, and is planned to start this month.

READ FULL MINDMED ARTICLE

6. Ayr Wellness: Analysts Anticipate US$108 Million in Q3 Revenue

Three Analysts Have Revenue Estimates for the Third Quarter, With the Average Projection Coming in at USD $108 Million

Ayr Strategies (CSE: AYR.A) (OTCQX: AYRSF) announced that they will be reporting their fiscal third quarter financials after hours on March 26th. Analysts have a consensus C$58 12-month price target on the company, via a total of 4 analysts, with one analyst having a strong buy rating and the other three having buy ratings. The street high comes from Beacon Securities with a C$76 price target.

READ FULL AYR ARTICLE

5. Can Psychedelics Actually Cure Depression and PTSD?

There is Now Data Suggesting That Magic Mushrooms and Ecstasy Combined With Talk Therapy May Help People With Severe Depression and Post-Traumatic Stress Disorder

Is there about to be a psychedelic drug boom in mental health treatment? In May researchers released data from a phase 3 trial that used MDMA (street name: ecstasy) along with talk therapy to treat people who have post-traumatic stress disorder (PTSD). And Compass Pathways (NASDAQ: CMPS) is exploring the use of psilocybin (the active ingredient in magic mushrooms) in combination with talk therapy, to treat people who have severe depression.

READ FULL CMPS ARTICLE

4. Cannabis Co Greenlane Holdings And KushCo Holdings Move a Step Closer to Merger

In March, the Companies Announced That KushCo Had Agreed to Become a Wholly-Owned Subsidiary of Greenlane Under an All-Stock Deal

Greenlane Holdings (NASDAQ: GNLN) and KushCo Holdings (OTCQX: KSHB) are one step closer to finalizing their recent merger. On Tuesday, the companies reported the expiration of the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the proposed merger.

READ FULL GNLN KSHB ARTICLE

3. Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Psilocybin Has Been Granted Breakthrough Therapy Designation by the U.S. FDA to Multiple Entities in the USA, and This Specific Trial Will Become the First of its Kind Comparing a 25mg Psilocybin Capsule With Cybins Proprietary Sublingual Film Formulation

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board (IRB) at the University of the West Indies Hospital, in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation (CYB001) in a Phase II clinical trial for patients suffering with Major Depressive Disorder (MDD). Commencement of the clinical trial is subject to final confirmation of study material specifications by Jamaicas Ministry of Health.

READ FULL CYBN ARTICLE

2. GrowGeneration Acquires The Harvest Company, Expands Footprint in Californias Emerald Triangle

Acquisition Brings Number of GrowGen Locations Nationwide to 55

GrowGeneration (NASDAQ: GRWG), the nations largest chain of specialty hydroponic and organic garden centers, today announced its acquisition of The Harvest Company, a northern California-based hydroponic supply center and cultivation design innovator with stores in Redding and Trinity County. The Harvest Company serves growers in Northern Californias Emerald Triangle the largest cannabis-producing region in the country.

READ FULL GRWG ARTICLE

1. MindMed Announces Launch of Collaboration with Nextage Therapeutics Brain Targeting Liposome System

Using This State-of-the-Art Drug Delivery Technology, MindMed is Seeking to Capitalize on the Opportunity to Mitigate the Serious Side Effects That Can Make Some Orally Administered Psychedelics Poor Drug Candidates

MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ) and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announced the execution of an MOU regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextages proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license. MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.

READ FULL MMED ARTICLE

See more from Benzinga

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the rest here:

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week - Yahoo Finance

NIH Director Touted Benefits of Psychedelics Including Psilocybin and MDMA – Stockhouse

Psychedelics may be one step closer to decriminalization. All after the Director of the National Institutes of Health (NIH), Francis Collins touted the benefits of psilocybin and MDMA, as noted by Marijuana Moment . There has been a resurgence of interest in psychedelic drugs, which for a while were sort of considered not an area that researchers legitimately ought to go after,” Collins said. And I think as we’ve learned more about how the brain works, we’ve begun to realize that these are potential tools for research purposes and might be clinically beneficial.” That support could be beneficial for companies, such as NeonMind Biosciences ( CSE:NEON) (OTC:NMDBF), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Mind Medicine Inc. (NEO:MMED) (NASDAQ:MNMD), HAVN Life Sciences Inc. (CSE:HAVN)(OTC:HAVLF), and Mydecine Innovations Group (CSE:MYCO)(OTC:MYCOF).

Studies have already shown that some psychedelics could be useful for treating anxiety, PTSD, opioid addictions, obsessive-compulsive disorder (OCD), and alcoholism. We may also soon learn psilocybin could potentially assist in treating eating disorders and obesity from a NeonMind Biosciences study. That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."

NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) to Commence Trading on OTCQB

NeonMind Biosciences announced that its shares will commence trading on the OTCQB® Venture Market on May 28, 2021, under the symbol NMDBF”. NeonMind will continue to trade on the Canadian Securities Exchange under its existing symbol NEON”.

The OTCQB, operated by OTC Markets Group Inc., is designed for early-stage and developing U.S. and international companies. Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities.

With this OTCQB listing, NeonMind has achieved a significant milestone in its mission to advance its psilocybin drug development programs,” said Robert Tessarolo, President & CEO of NeonMind. We expect this listing to increase our financial capabilities and expand our exposure to the U.S. investment community. This capital markets support will be extremely valuable as we continue to execute on our long-term strategy to advance the use of therapeutic psychedelic compounds for weight management conditions including obesity, which is a growing global health crisis.”

Other related developments from around the markets include:

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries. The application, governed by the Patent Cooperation Treaty, grants the Company the right to file future national applications into treaty member jurisdictions, including important potential markets for the Company. The PCT claims a library of psychedelic derivative drug development candidates.

Mind Medicine Inc., a leading psychedelic medicine biotech company, announced the publication of the first pharmacogenetic data on LSD to help personalize dosing . The study results from a pooled secondary analysis of four Phase 1 studies that each used a randomized, double-blind, placebo-controlled, crossover design and were conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland. The results of this study indicate that pharmacogenetic testing prior to LSD-assisted treatment may inform LSD dose selection at the individual patient level.

HAVN Life Sciences Inc., biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce a production and supply agreement with Lobe Sciences Ltd. , an innovative biotech company committed to investigating and developing treatments using psychedelic and non-traditional medicines for better brain health. Pursuant to the Agreement, HAVN Life will produce and supply an offering of Natural Health Products, which will include plant-based compounds and non-psychoactive mushrooms. The Agreement with Lobe Sciences will create an additional revenue stream for HAVN Life, and the team will look to generate additional agreements in the coming months.

Mydecine Innovations Group said that it has received approval from Health Canada to significantly expand” its cultivation capabilities at its current good manufacturing practice (cGMP) facility, at the Applied Pharmaceutical Innovation in Canada. The Denver, Colorado-based biopharma company focused on the research and development of alternative nature-sourced medicine, said that it would use the new guidance from Health Canada to expand its cultivation facilities and rapidly scale up the supply of pharmaceutical-grade psilocybin for both its internal clinical research and for its industry partners. The increased cultivation will also allow the company to more efficiently and quickly study the medical utility of naturally occurring psilocybin and psilocybin-like compounds,” said the company.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Inc. Please click here for full disclaimer.

Contact Information: 2818047972 ty@LifeWaterMedia.com

Here is the original post:

NIH Director Touted Benefits of Psychedelics Including Psilocybin and MDMA - Stockhouse

Texas Psychedelics Research Bill Continues To Advance, Passes Senate Together With Cannabis Concentrates Measure – Benzinga

A psychedelics-related bill and acannabis-focused measure were both given thegreen light by the Texas Senate this Saturday and Friday, respectivelyreported Marijuana Moment.

House bill 1802 to research the therapeutic effects of psilocybin and MDMA was first presented in February by Texas state Rep. Alex Dominguez (D). The initiative requires the Department of State Health Services and Texas Medical Board to study psilocybin, MDMAand ketamine for the treatment of post-traumatic stress disorder (PTSD) and other health conditions.

Research would be conducted at the Baylor College of Medicine and a military veterans hospital or a medical center that provides medical care to veterans, as the bill was amended by a House committee to place a special focus on veterans with PTSD.

The bill wasapprovedin the House earlier this month and last Wednesday it also passed Senate Veteran Affairs and Border Security Committee in a 5-0 vote.

Instead of hitting Gov. Greg Abbotts desk, both bills must goback to their initial chamber because they were amended by senators, noted the outlet.

A balanced budget amendment to the bill, which the Senate approved, states that psychedelic research cannotbe conducted if there is no funding to support it.

The cannabis-related measure that was approved by the Texas Senate would make possession of up to two ounces of concentrates a class B misdemeanor. As a class B misdemeanor, the offense is still subject to the threat of jail time but is much less serious than the felony classification, which such an offense normally warranted.

An amendment to this bill added by senators asksthat when calculating THC potency in legal hemp products all forms of tetrahydrocannabinol must be included.

Photo by Janet Reddick at Pixaby

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Go here to see the original:

Texas Psychedelics Research Bill Continues To Advance, Passes Senate Together With Cannabis Concentrates Measure - Benzinga

With Psychedelics, Mental Health Care May Never be the Same – Baystreet.ca

With psychedelics, mental health care may never be the same. All as some of the nations top universities are racing to set up psychedelic research centers, and investors are pouring millions of dollars into a pack of start-ups. States and cities across the country are beginning to loosen restrictions on the drugs, the first steps in what some hope will lead to the federal decriminalization of psychedelics for therapeutic and even recreational use, as reported by The New York Times. Thats been substantial news for NeonMind Biosciences (CSE:NEON) (OTC:NMDBF), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Tryp Therapeutics Inc. (CSE:TRYP), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), and Compass Pathways (NASDAQ:CMPS).

Not only has the US FDA been supportive of psychedelics, Johns Hopkins, Yale, Berkeley, and Mount Sinai Hospital are establishing psychedelic divisions, as well. Plus, theres been a substantial proof psychedelics can help with issues such as depression, anxiety, addiction, obsessive compulsive disorder, and obesity.

In fact, NeonMind Biosciences is exploring psilocybin as a potential treatment for obesity and to support weight loss. In fact, NeonMinds first drug candidate employs psilocybin as an agonist to the serotonin receptor 5-HT2A, which is involved in the hallucinogenic effect of psychedelics. The second drug candidate employs psilocybin as an agonist to the serotonin 5-HT2C receptor, which controls appetite.

NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) Creating a Medical Advisory Board

NeonMind Biosciences an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce the formation of a Medical Clinic Advisory Board to guide the planning and operation of NeonMind branded clinics across Canada. Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.

The formation of our Medical Clinic Advisory Board is a critical next step in the creation of our clinics and treatment models. By incorporating a team of experts specializing in mental healthcare, interventional psychiatric treatment, psychedelics, and clinical deployment, operations, and advocacy, we are achieving the next step in our strategic plan to increase treatment access in local markets across Canada, said Robert Tessarolo, President & CEO of NeonMind.

Currently, ketamine and esketamine may legally be prescribed and administered in Canadian medical clinics, however there is a need for these clinics and treatments to be tailored to community and local health needs. As psychedelic drug development and treatment programs evolve to include additional psychedelic-enhanced therapies with substances like psilocybin, NeonMind will be positioned to have the infrastructure in place to safely and effectively administer these treatments.

Our Medical Clinic Advisory Board will ensure that NeonMind is able to develop protocols and treatment programs at the cutting edge of mental health research and ensure that we are prioritizing value, access and advocacy for those who need them, added Rob Tessarolo.

Other related developments from around the markets include:

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed a new provisional patent application in support of its ongoing drug candidate programs. The application discloses novel compositions which are expected to have improved pharmacokinetic profiles while retaining key efficacy measures of the original molecules and discloses innovative methods of deploying the novel compositions with faster therapeutic onset of Cybins psychedelic tryptamine, while reducing psychedelic side effects and decreasing duration of the therapeutic effect thereof.

Tryp Therapeutics Inc., a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced a master service agreement with Clinlogix, a Contract Research Organization (CRO), to support Tryps clinical development of its Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program. Clinlogix has global experience with providing CRO services for the development of novel pharmaceutical products. The company will collaborate with Tryp and its clinical partners in a number of areas including medical writing, biostatistical analysis, data management, and trial monitoring.

Mind Medicine Inc., a leading clinical stage psychedelic medicine company, and Nextage Therapeutics, an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextages proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license. MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.

Compass Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the first quarter 2021 and gave an update on recent progress across its business. George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, Our recent financing gives us additional resources to work even faster and to expand our efforts, grow our team, and focus on developing new indications, new compounds and new technologies, building on our leadership position in psilocybin therapy and mental health care. Far too many people are suffering with mental health challenges today. We are focused on developing evidence-based therapies that can make a difference and be accessible to as many patients as possible who might benefit. The COMP360 data published in the New England Journal of Medicine showed promising signals in a small investigator-initiated study. We are approaching the completion of our phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression, and on track to report data by the end of the year.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Inc. Please click here for full disclaimer.

Contact Information: 2818047972[emailprotected]

See original here:

With Psychedelics, Mental Health Care May Never be the Same - Baystreet.ca

Wesana Health, WBC Partner to Study Psychedelics as Treatment for TBIs – StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Daniel Carcillo retired from the National Hockey League in 2015, after nine seasons in the game. He had been diagnosed with several concussions and had struggled with insomnia, depression, anxiety, headaches and even slurred speech in his professional seasons as a hockey player.

Determined to get better, Carcillo implemented lifestyle changes that included the use of psilocybin, an active ingredient found in magic mushrooms, as well as eating healthier and getting more sleep. This, he said, helped improve his overall heath tremendously&

Read more >>

NOTE TO INVESTORS:The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the companys newsroom athttps://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) createsPsychedelicNewsBreaksdesigned to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text Groovy to 21000 (U.S. Mobile Phones Only)

For more information please visithttps://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW?Ask our Editor

PsychedelicNewsWire (PNW)San Francisco, Californiawww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicWire.com

PsychedelicNewsWire is part of theInvestorBrandNetwork.

Go here to see the original:

Wesana Health, WBC Partner to Study Psychedelics as Treatment for TBIs - StreetInsider.com

What is that?! SpaceX’s Starlink satellites explained – EarthSky

View at EarthSky Community Photos. | Here at EarthSky, were receiving many excited emails about sightings of lights traveling together across the night sky. UFOs? No. Usually, people are seeing Starlink satellites. Roger Oban in Tucson, Arizona, captured this photo of Starlinks on May 5, 2021. He wrote: Shot in my backyard. I was just about to shut down, when 5 satellites came through, all in a straight line. Thank you, Roger!

Starlink is the name of a satellite network that SpaceX is developing to provide global broadband coverage for high-speed internet access, particularly for people across the world in rural and remote areas. SpaceX has launched more than 600 new Starlinks this year,typically launching 60 at a time.As of last week, that places the number of Starlink satellites currently in orbit at more than 1,500. Over the coming few years, SpaceX plansto send up at least 12,000 Starlink satellites.Satellite internet is beamed through space at a rate thats reportedly 47% faster than fiber-optic cable internet. All well and good. But the Starlinks are bright. Theycan be seen in the night sky. Each launch creates whats being called megaconstellations groups of satellites moving together. Is2021s sudden upsurge in the number of Starlink satellites also causing UFO sightings to increase? Plus, astronomers are worried. The Starlink satellitesare photobombingastronomical images. They have the potential to interferewith the professional observations that have brought us our modern-day view of the cosmos.

The proposal for Starlink was announced by SpaceX CEO Elon Musk back in January 2015. Though it wasnt given a name at the time, Musk said that the company had already filed documents withinternational regulators to place about 4,000 satellites in low-Earth orbit. He said in a speech when revealing the project:

Were really talking about something that is, in the long term, like rebuilding the internet in space.

And his predictions so far have proven true. Musks initial estimate of the number of satellites quickly grew, as he hoped to capture a part of the estimated $1 trillion worldwide internet connectivity market. The U.S. Federal Communications Commission (FCC) has granted SpaceX permission to fly 12,000 satellites, and perhaps as many as 30,000 eventually. To put things into perspective: only about 2,000 operational satellites currently orbit Earth. Fewer than 9,000 have ever been launched in all of history, according to the United Nations Office for Outer Space Affairs. Starlink satellites orbit at an altitude of 340 miles (550 km). At that height, theyre low enough to get pulled down to Earth by atmospheric drag and burn up in a few years, so that they dont become space junk once they die (a problem SpaceX may hope to tackle using Starship). Each one weighs 500 pounds (227 kg), and measures about the size of a typical coffee table, according to Skyandtelescope.com.

It was exciting to see the first few Starlink satellites, traveling together in the night sky. But then more were launched, and then more. And astronomers began to worry.

SpaceXs two test satellites, TinTinA and TinTinB, launched in 2018. The mission went smoothly. Using that initial data, the company decided it wanted its fleet to operate lower than originally planned. Regulators deliberated and the FCC approved the move.

The first 60 Starlink satellites were successfully launched on May 23, 2019, aboard a SpaceX Falcon 9 rocket. Members of the Starlink team plan to launch up to 60 more per Falcon 9 flight, with launches as often as every two weeks in 2021. Of the 15 Falcon 9 launches so far this year, all have been dedicated to lofting 60 Starlink satellites apart from two, bringing the total number launched so far this year to 722 as of today. One the Transporter-1 rideshare mission in January carried only 10 satellites, and the other the Capella Space rideshare mission launched last Saturday carried 52.

Starlink controversy within the astronomy community. Despite the promise of high-speed broadband internet, SpaceX has taken criticism within the astronomical community for its Starlink satellites, due to their brightness and potential to disrupt observations of the night sky. The National Science Foundation and the American Astronomical Society released a report on the situation in August 2020. Discussions among more than 250 experts at the virtual Satellite Constellations 1 (SATCON1) workshop expressed concern that the bright train of satellites marching across the sky will hinder their observations.

In response, SpaceX has begun outfitting their satellites with a blackened sunshade called VisorSat that the company hopes will reduce the satellites apparent brightness by reducing the amount of sunlight thats reflected. This is just one of the six suggestions proposed by the SATCON1 team. Initial efforts at mitigating the spacecrafts impact involved launching a prototype Starlink satellite later dubbed DarkSat earlier this year, which features a black antireflective coating. Recent ground-based observations of DarkSat in orbit found it half as bright as a standard Starlink satellite, which is a good improvement, according to experts, but still far from what astronomers say is needed. Jeremy Tregloan-Reed, a University of Antofagasta astronomer on the observational team that assessed the prototype, commented:

I would not consider DarkSat as a victory but instead a good step in the right direction.

The team compared DarkSat with a typical Starlink sibling using a two-foot (0.6-m) telescope at the Ckoirama Observatory in Chile and found that although DarkSats antireflective coating rendered it invisible to the unaided eye, it remains far too bright to avoid interfering with the Vera C. Rubin Observatory now under construction in Chile and other major telescopes. Additionally, DarkSats darker color retains too much heat, so the company is sticking with the visor alternative instead.

Astronomers are hoping to observe VisorSat and compare it with DarkSat once observatories reopen following the Covid-19 shutdown. With SpaceXs plans, plus Amazons Kuiper project, OneWeb, Chinas Hongyan, and other projects launching their own global networks of hundreds or thousands of satellites with little to no regulation, the scale of astronomys satellite-constellation problem might only increase.

Bottom line: Have you seen a group of bright satellites crossing the night sky together? They are likely SpaceX Starlink satellites, which create relatively bright, large, moving megaconstellations. Starlinks goal is to provide global broadband coverage for high-speed internet access, especially for rural and remote areas. Astronomers and skywatchers worry about Starlinks potential to interfere with their work understanding the universe, and their enjoyment of the night sky.

Lia De La Cruz is a Physics graduate and Editorial Assistant of EarthSky, contributing also as a field correspondent with a long-time passion for space exploration that began early in her college career. She started her blog SkyFeed in 2018, which earned a mention in Feedspots Top 50 Space Blogs to Follow," has been published in Smore Magazine, and led her to launch a communications career in tandem with her planetary passion. She currently resides in Southern California with her husband and small pug pup.

Here is the original post:

What is that?! SpaceX's Starlink satellites explained - EarthSky

SpaceX Rival OneWeb Plans Next-Gen Constellation Thats Better Than Starlink – Observer

With more than 1,000 Starlink satellites beaming internet signals from the sky, SpaceX is leading the race of constellation-based broadband service. But its ambitious launch plan makes space environmentalists nervous: SpaceX has applied for regulatory permission to deploy 42,000 Starlink satellites over the next few years in low Earth orbit, an area already increasingly crowded with manmade objects and debris. Thats perhaps why Starlinks main competitor, U.K.-based OneWeb, despite having launched fewer than 200 satellites, is looking to develop a more efficient version of the emerging technology.

A consortium of space firms led by OneWeb has secured $45 million in funding from the British government to launch a beam-hopping satellite next year to test a second-generation network it aims to launch in 2025.

These new satellites, called Joey-Sat, are designed to be able to direct beams to increase capacity in specific areas in response to demand spikes or emergencies. From helping during a disaster to providing broadband on planes, this amazing technology will show how next-generation 5G connectivity can benefit all of us on Earth, U.K. Science Minister Amanda Solloway said in a statement Monday.

OneWeb is teaming up with antenna maker SatixFy, ground station builder Celestia and space debris removal startup Astroscale. The pilot mission is funded by the U.K. Space Agency through the European Space Agencys Sunrise program.

SatixFy, which receives the largest chunk of the fund ($35 million), will be tasked to build Joey-Sats beam-hopping payload and user terminals.

In March, SatixFy agreed to build an in-flight connectivity terminal for OneWebs existing LEO constellation. The company has a similar deal with the Canadian satellite operator Telesat, providing modem chips that will support beam hopping for Telesats Lightspeed LEO constellation project.

Celestia will build and test ground stations for Joey-Sat that feature a new multi-beam, electronically steered antenna. Astroscale is commissioned to develop technologies that could safely de-orbit these satellites when theyre dead so that they wont become free-floating space junk.

This ambitious project with OneWeb is the next step towards maturing our technologies and refining our U.K. capabilities to develop a full-service Active Debris Removal offering by 2024, Astroscale U.K. managing director John Auburn said in a statement.

OneWeb is partly owned by the U.K. government. The company aims to begin satellite broadband service to north of 50 degrees latitude by June, which would cover the U.K., northern Europe, Greenland, Iceland, Canada and Alaska.

See the rest here:

SpaceX Rival OneWeb Plans Next-Gen Constellation Thats Better Than Starlink - Observer

Close Up Photo Shows the SpaceX Resilience Capsule Still Tied to the ISS – autoevolution

Back at the beginning of May, the first-ever crew to have been transported with the SpaceX Crew Dragon capsule to the International Space Station (ISS) came back to Earth. They made the journey back home in the spacecraft called Resilience, and they arrived safely in what became the first nighttime landing in over 50 years.

The Crew Dragon is seen in this shot shortly before undocking from the ISS. That means all four Crew-1 astronauts (Shannon Walker, Victor Glover, Mike Hopkins, and Soichi Noguchi) were already on board when it was taken, and the spacecraft is shown still held in place by the docking adapter of the stations Harmony module.

We thought it would be relevant to bring Resilience back into focus because this is the ship Elon Musks space faring company will use to send a crew of four civilians on a short trip around the planet. The launch is scheduled for sometime this fall.

The four people that will probably become the first tourists to go around the planet in a spaceship (Blue Origins launch will be only a trip up and down) are billionaire Hayley Arceneaux, Lockheed Martin engineer Christopher Sembroski, scientist-teacher Sian Proctor, and the man bringing the money to the mission, billionaire and former pilot Jared Isaacman.

The mission that will be taking them up is called Inspiration4 and is described as a charitable trip meant to help raise $200 million for St. Jude Childrens Research Hospitals efforts to fight childhood cancer.

Go here to see the original:

Close Up Photo Shows the SpaceX Resilience Capsule Still Tied to the ISS - autoevolution